Proniras is a specialty pharmaceutical brand dedicated to developing innovative drugs for neurological conditions with high unmet medical needs. Their flagship program, tezampanel, is a groundbreaking AMPA/kainate receptor antagonist that effectively counteracts glutamate signaling in the central nervous system (CNS). Glutamate, the primary excitatory neurotransmitter in the CNS, plays a crucial role in withdrawal symptoms associated with opiate abuse.

Proniras aims to address this issue by preventing a glutamate-driven over-agitation of the nervous system, which leads to excruciating physical and psychological symptoms during withdrawal. By offering relief from withdrawal symptoms, Proniras hopes to break the cycle of addiction and facilitate the path to sobriety. Additionally, tezampanel shows potential for treating other neurological conditions, such as status epilepticus, pediatric epilepsy, neonatal abstinence syndrome, and CNS disruptions resulting from chronic alcohol abuse or exposure to nerve agents.

Established in 2017 by Accelerator Life Science Partners and Christopher Toombs, PhD, DABT, Proniras is headquartered in Seattle, Washington